Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9MW2821 plus toripalimab in locally advanced or metastatic urothelial carcinoma
CTR20232677Phase 2Active
- Sponsor
- Mabwell
- Start
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of bulumtatug fuvedotin, toripalimab in transitional cell carcinoma (TCC), sponsored by Mabwell. Started Sep 2023; status: active.
02
Drugs
bulumtatug fuvedotintoripalimab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20232677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232677.